• US: +1-408-610-2300
  • Toll Free: +1-866-831-4085
  • Login / Register
  • Home
  • » Healthcare IT
  • » Pharmacovigilance Market Size, Share, Trends, 2025 | Industry Report
Pharmacovigilance Market Size, Share, Trends, 2025 | Industry Report

Pharmacovigilance (PV) Market Size & Forecast Report, 2014 - 2025

Report ID: MN17613653  |  Published: July 2017  |  No of Pages: 129
Format: Electronic (PDF)  |  Industry: Healthcare IT  |  Publisher: Grand View Research

The global Pharmacovigilance (PV) Market size is estimated to reach USD 10.27 billion by 2025, registering at a 13.1% CAGR over the forecast period as the scope and its applications are rising enormously across the globe. Pharmacovigilance (PV) is also termed as drug safety, is a science and activities relating to the prevention, detection, understanding, and assessment of adverse effects or other drug-related issues.

The factors that are playing a major role in the growth of pharmacovigilance market are the rising occurrence of adverse drug reactions (ADR), enhancement in development of ADR database and information system, and the rising demand from the end-users. Pharmacovigilance (PV) industry is segmented based on the clinical trial phase, service provider, type of methods, end-user, and region.

Phase IV, phase III, phase II, phase I, and pre-clinical are the clinical trial phase that could be explored in pharmacovigilance (PV) market in the forecast period. The phase IV sector accounted for the substantial market share of pharmacovigilance and is estimated to lead the overall market in the years to come. Also, phase III sector is estimated to show lucrative growth in the years to come. Contract outsourcing, in-house, and other service providers could be explored in pharmacovigilance industry in the forecast period. Contract outsourcing sector accounted for the substantial market share of pharmacovigilance and is estimated to lead the overall market in the years to come.

Based on the type of method, HER mining, spontaneous reporting, cohort event monitoring, intensified ADR reporting, targeted spontaneous reporting, and others could classify pharmacovigilance market in the forecast period. Spontaneous report sector accounted for the significant market share of pharmacovigilance and is estimated to continue its dominance in the years to come. Also, the cohort event monitoring sector is estimated to grow at the fastest pace in the years to come.

The market may be categorized based on end-users like industrial, hospitals, research organizations, and others that could be explored in the forecast period. The hospitals sector accounted for the substantial market share of pharmacovigilance and is estimated to lead the overall market in the years to come. Also, the research organization sector is estimated to grow at the fastest pace in the years to come.

Globally, North America accounted for the substantial share of pharmacovigilance industry and is estimated to lead the overall market in the years to come. The reason behind the overall market growth could be the presence of key manufacturers in the region and the high investment in the development of new drugs. The United States and Canada are the major consumers of pharmacovigilance in the years to come.

Europe and the Asia Pacific are also estimated to have a positive influence on future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at the highest CAGR in the forecast period. The developing countries like India and China are the major consumers of pharmacovigilance in this region.

The key players of pharmacovigilance (PV) industry are United BioSource Corporation, Accenture, Wipro Ltd., Clinquest Group B.V., BioClinica, Cognizant, PAREXEL International Corporation, Laboratory Corporation of America Holdings, TAKE Solutions Ltd., IBM Corporation, Foresight Group International AG, ArisGlobal, and iMEDGlobal. These players are concentrating on inorganic growth to sustain themselves amidst fierce competition.

Market Segment:

Pharmacovigilance Clinical Trial Phase Outlook (Revenue, USD Million, 2014 - 2025)
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
    • Phase IV

Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2014 - 2025)
    • In-house
    • Contract Outsourcing

Pharmacovigilance Type of Methods Outlook (Revenue, USD Million, 2014 - 2025)
    • Spontaneous Reporting
    • Intensified ADR Reporting
    • Targeted Spontaneous Reporting
    • Cohort Event Monitoring
    • EHR Mining

Pharmacovigilance End Use Outlook (Revenue, USD Million, 2014 - 2025)
    • Hospitals
    • Research Organizations
    • Industrial

Pharmacovigilance Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
        • U.S.
        • Canada
    • Europe
        • UK
        • Germany
    • Asia Pacific
        • Japan
        • China
        • India
    • Latin America
        • Brazil
        • Mexico
    • MEA
        • South Africa

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service
  • 100% Secure Payments
  • Our Promise
  • 100% Service Assurance
  • Market Monitoring
  • Service Flexibility
  • 24X5 Care available